Camptothecin delivery systems: The antitumor activity of a Camptothecin-20-0-polyethylene glycol ester transport form

Anticancer Research

Volumn 17, Issue 5 A, 1997, Pages 3361-3368

  Conover, Charles D ^a   Pendri, Annapurna ^a   Lee, Chyi ^a   Gilbert, Carl W ^a   Shum, Kwok L ^a   Greenwald, Richard B ^a  

^a Enzon Incorporated   (United States)

Author keywords

Camptothecin, prodrug; Mouse; Polyethylene glycol; Xenograft

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; MACROGOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MODEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG RETENTION; DRUG TRANSPORT; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LEUKEMIA, EXPERIMENTAL; MICE; MICE, INBRED STRAINS; MICE, NUDE; NEOPLASM TRANSPLANTATION; POLYETHYLENE GLYCOLS; PRODRUGS; TUMOR CELLS, CULTURED; VEHICLES;

EID: 0030781081     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Wall M and Wani M: Camptothecin and taxol: from discovery to clinic. J of Ethnopharmacol 51: 239-254, 1996.
2. Burris H and Fields S: Topoisomerase I inhibitors: An overview of the camptothecin analogs. New Drug Ther 8: 333-355, 1994.
3. Tsao Y, D'Arpa P and Liu L: The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of P34cdc2/cyclin B1. Cancer Res 52: 1823-1829, 1992.
4. Giovanella B, Hinz H, Kozielski A, Stehlin J, Silber R and Potmesil M: Complete growth inhibition of human cancer xenograft in nude mice by treatment with 20-(S)-camptothecin. Cancer Res 51: 3052-3055, 1991.
5. Potmesil M: Camptothecins: From Bench Research to Hospital Wards. Cancer Res 54: 1431-1439, 1994.
6. Pantazis P: Preclinical studies of water-insoluble camptothecin congeners: Cytotoxicity, development of resistance, and combination treatments. Clin Can Res 1: 1235-1244, 1995.
7. Kingsbury W, Boehm J, Jakas D, Holden K, Hecht S, Gallagher G, Caranfa M, McCabe F, Faucette L, Johnson R and Hertzberg R: Synthesis of water-soluble (aminoalkyl)camptothecin analogues: Inhibition of topoisomerase I and antitumor activity. J Med Chem, 34: 98-107, 1991.
8. Sawada S, Okajima S, Aiyama R, Nokata K, Furuta T, Yokokura T, Sugino E, Yamaguchi K and Miyasaka T: Synthesis and antitumor activity of 20(S)-camptothecin derivatives: carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin. Chem. Pharm Bull 10: 1451-1457, 1991.
9. Supko J. and Malspeis L: Pharmacokinetics of the 9-amino and 10,11-methylenedioxy derivatives of camptothecin in mice. Cancer Res 53: 3062-3069, 1993.
10. Slichenmeyer W, Rowinsky E, Donehower R and Kaufmann S: The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85: 271: 291, 1993.
11. Rao Vishnuvajjala B. and Garzon-Aburbeh A: Water Soluble Prodrugs of Camptothecin U.S. Patent, 4,943,579, 1990.
12. Bundgaard H: Bioreversible derivatization of peptides. In: Delivery Systems for Peptide Drugs (Davis S., Ilium, L. and Tomlinson, E. eds). New York: Plenum Press, 1986, pp 49-68.
13. Greenwald R., Gilbert C., Pendri A., Conover C., Xia J. and Martinez A: Drug delivery systems. Water soluble taxol 2'-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. J Med Chem 39: 424-431, 1996.
14. Oliyai R. and Stella V: Prodrugs of peptides and proteins for improved formulation and delivery. Annu. Rev. Pharmacol. Toxicol., 32:521-544, 1993.
15. Greenwald R, Pendri A, Conover C, Gilbert C, Yang R and Xia J: Drug delivery systems. 2. Camptothecin 20-O-poly(ethylene glycol) ester transport forms. J Med Chem 39: 1938-1940, 1996.
16. Burnham N: Polymers for delivering peptides and proteins. Amer J Hosp Pharm 51: 210-218, 1994.
17. Nucci M, Shorr R and Abuchowski A: The therapeutic value of poly(ethylene glycol)-modified proteins. Adv Drug Del Rev 6: 133-151, 1991.
18. Emerson D, Besterman J, Brown H, Evans M, Leitner P, Luzzio M, Shaffer J, Sternhach D, Uehling D and Vuong A: In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues. Cancer Res 55: 603-609, 1995.
19. Wall M and Wani M: Antineoplastic agents form plants. Ann Rev Pharmacol Toxicol 17: 117-132, 1977.
20. Rivory L and Robert J: Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives. Pharmac Ther 68: 269-296, 1995.
21. Burke T and Mi Z: Ethyl substitution at the 7 position extends the half-life of 10-hydroxycamptothecin in the presence of human serum albumin. J Med Chem 36: 2580-2582, 1993.
22. Burke T and Mi Z: The structural basis of camptothecin interactions with serum albumin: Impact on drug stability. J Med Chem 37: 40-46, 1944.
23. Mi Z and Burke T: Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry, 33: 10325-10336, 1994.
24. Wall M, Wani M, Cook C, Palmer K, McPhail A and Sim G: Plant antitumor agents. I. The isolation and structure of camptothecin a novel alkaloidal leukemia and tumor inhibitor from "Camptotheca acuminata". J Am Chem Soc 88: 3888-3890, 1966.
25. Pantazis P, Kozielski A, Vardeman D, Petry E and Giovanella B: Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts. Oncology Res 5: 273-281, 1993.
26. Hertzberg R, Caranfa M, Holden K, Jakaa D, Gallagher G, Mattern M, Mong S, Bartus J, Johnson R and Kingsbury W: Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32: 715-720, 1989.
27. Schappei U, Fleischman R and Cooney D: Toxicity of camptothecin (NSC-100800). Cancer Chemother Rep 5: 25-36, 1974.
28. Giovanella B, Stehlin J, Wall M, Wani M, Nicholas A, Liu L, Silber R and Potmesil M: DNA topoisomerase I - target chemotherapy of human colon cancer in xenografts. Science 246: 1046-1048, 1989.
29. Maeda H, Seymour L and Miyamota Y: Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjugate Chem 3: 351-362, 1992.
30. Dvorak H, Nagy J, Dvorak J and Dvorak A: Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 138: 95-109, 1988.
31. Trouet A: Increased selectivity of drugs by linking to carriers. Euro J Cancer 14: 105-111, 1978.
32. Seymour L: Passive tumour-targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Syst 9: 135-187, 1992.